Transplantation Biology Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Am J Transplant. 2011 Jun;11(6):1236-47. doi: 10.1111/j.1600-6143.2011.03566.x.
We recently reported long-term organ allograft survival without ongoing immunosuppression in four of five patients receiving combined kidney and bone marrow transplantation from haploidentical donors following nonmyeloablative conditioning. In vitro assays up to 18 months revealed donor-specific unresponsiveness. We now demonstrate that T cell recovery is gradual and is characterized by memory-type cell predominance and an increased proportion of CD4⁺ CD25⁺ CD127⁻ FOXP3⁺ Treg during the lymphopenic period. Complete donor-specific unresponsiveness in proliferative and cytotoxic assays, and in limiting dilution analyses of IL-2-producing and cytotoxic cells, developed and persisted for the 3-year follow-up in all patients, and extended to donor renal tubular epithelial cells. Assays in two of four patients were consistent with a role for a suppressive tolerance mechanism at 6 months to 1 year, but later (≥ 18 months) studies on all four patients provided no evidence for a suppressive mechanism. Our studies demonstrate, for the first time, long-term, systemic donor-specific unresponsiveness in patients with HLA-mismatched allograft tolerance. While regulatory cells may play an early role, long-term tolerance appears to be maintained by a deletion or anergy mechanism.
我们最近报道了在接受非清髓性预处理的 HLA 错配供者肾和骨髓联合移植的 5 例患者中,4 例患者在无持续免疫抑制的情况下实现了长期器官同种异体移植物存活。长达 18 个月的体外检测显示供者特异性无反应性。我们现在证明,T 细胞的恢复是渐进的,其特征是记忆样细胞优势增加,以及在淋巴细胞减少期 CD4⁺ CD25⁺ CD127⁻ FOXP3⁺ Treg 的比例增加。所有患者在 3 年的随访中,在增殖和细胞毒性检测以及 IL-2 产生细胞和细胞毒性细胞的有限稀释分析中均表现出完全的供者特异性无反应性,并扩展至供者肾小管上皮细胞。在 4 例患者中的 2 例中,在 6 个月至 1 年的检测中发现了一种抑制性耐受机制发挥了作用,但在所有 4 例患者中进行的更晚期(≥18 个月)研究并未提供抑制性机制的证据。我们的研究首次证明了 HLA mismatched 同种异体移植耐受患者的长期、系统性供者特异性无反应性。虽然调节性细胞可能发挥早期作用,但长期耐受似乎是通过删除或无能机制维持的。